Editas Medicine, Inc. (EDIT)
| Market Cap | 299.10M +131.1% |
| Revenue (ttm) | 38.69M +8.0% |
| Net Income | -108.95M |
| EPS | -1.18 |
| Shares Out | 97.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 584,627 |
| Open | 3.230 |
| Previous Close | 3.175 |
| Day's Range | 3.030 - 3.250 |
| 52-Week Range | 1.290 - 4.537 |
| Beta | 2.14 |
| Analysts | Strong Buy |
| Price Target | 5.40 (+76.76%) |
| Earnings Date | May 5, 2026 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ... [Read more]
Financial Performance
In 2025, Editas Medicine's revenue was $40.52 million, an increase of 25.39% compared to the previous year's $32.31 million. Losses were -$160.06 million, -32.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for EDIT stock is "Strong Buy." The 12-month stock price target is $5.4, which is an increase of 76.76% from the latest price.
News
Editas Medicine reports Q1 EPS (26c), consensus (24c)
Reports Q1 revenue $2.83M, consensus $5.94M. “In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, towar...
Editas Medicine Announces First Quarter 2026 Results and Business Updates
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data ...
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine price target raised to $15 from $13 at Evercore ISI
Evercore ISI raised the firm’s price target on Editas Medicine (EDIT) to $15 from $13 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid
Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents
Editas Medicine (EDIT) announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s previous decision favoring the Broad Institute in the U.S. patent interference...
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing in vivo CRISPR therapies, with EDIT-401 showing 90% LDL-C reduction in preclinical models and a strong safety profile. Human proof-of-concept data is expected by year-end, targeting high-risk hyperlipidemia patients, and the pipeline includes additional programs leveraging proprietary technology.
Editas Medicine upgraded to Buy from Hold at JonesResearch
JonesResearch analyst Soumit Roy upgraded Editas Medicine (EDIT) to Buy from Hold with an $8 price target With Editas nearing IND/CTA submission of their heterozygous familial hypercholesterolemia gen...
Editas Medicine reports Q4 EPS (6c), consensus (26c)
Reports Q4 revenue $24.741M vs $30.604M last year. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clini...
Editas Medicine Transcript: TD Cowen 46th Annual Health Care Conference
Focused on in vivo CRISPR editing, the lead program aims for human proof of concept by year-end, targeting a 90% LDL cholesterol reduction in high-risk patients. The approach leverages non-coding DNA edits, robust preclinical data, and a scalable LNP platform, with financial runway into Q3 2027.
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Genflow Biosciences PLC Announces Directorate Change
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Editas Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference
A novel CRISPR-based LDLR upregulation strategy achieved a 90% LDL cholesterol reduction in preclinical models, with plans to target HeFH patients first and expand to broader populations. Human proof-of-concept data is expected by end of 2026, and cash runway extends to Q3 2027.
Editas Medicine price target lowered to $3.50 from $12 at Chardan
Chardan lowered the firm’s price target on Editas Medicine (EDIT) to $3.50 from $12 and keeps a Buy rating on the shares. The firm updated its Editas model for Q3
Editas Medicine price target raised to $4.60 from $4 at Clear Street
Clear Street raised the firm’s price target on Editas Medicine (EDIT) to $4.60 from $4 and keeps a Buy rating on the shares following the Q3 report. The company maintained
Editas Medicine reports Q3 EPS (28c), consensus (38c)
Reports Q3 revenue $7.54M, consensus $4.94M. “We are incredibly excited by the progress we made in the third quarter advancing our lead in vivo development candidate, EDIT-401, an experimental, potent...
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company...
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Editas Medicine management to meet with Cantor
Meeting to be held in Denver on October 27 and in San Francisco on October 28 hosted by Cantor Published first on TheFly – the ultimate source for real-time, market-moving
Editas Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Industry leaders discussed advances in genome editing, emphasizing the coexistence of diverse editing technologies and the critical role of delivery systems. Commercial success hinges on transformational efficacy, cost-effective delivery, and strategic indication selection, with multiple approvals anticipated in the coming years.
Editas Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
EDIT-401 targets a 90% LDL cholesterol reduction with a single-dose, durable CRISPR therapy, aiming for IND/CTA filing by mid-2026 and human proof-of-concept by year-end 2026. The program leverages unique upregulation, robust preclinical data, and a strong financial position into Q2 2027.
Editas Medicine reports in vivo preclinical PoC data for EDIT-401
Editas Medicine (EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, one-time therapy to significantly reduce LDL-cholesterol, at the 32nd Annual European Society o...
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% ...
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...